TD Cowen began coverage of Nektar Therapeutics on July 2, 2026, coinciding with an insider selling 5,538 shares of the company's stock.
1 report, 1 independent
Updated Jul 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen began coverage of Nektar Therapeutics on July 2, 2026, coinciding with an insider selling 5,538 shares of the company's stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
-
Nektar Therapeutics
American healthcare company
Nothing else this week.
Related events
- Leerink Partners assumed coverage on Nektar Therapeutics shares on October 13, 2026.
- TD Cowen initiated coverage on Citizens Financial Group shares.
- TD Cowen upgraded Maze Therapeutics shares to a strong-buy rating, with coverage reported by MarketBeat.
- TD Cowen issued research notes on GE Vernova stock on July 1, 2026.
- TD Cowen reaffirmed a buy rating on Tectonic Therapeutic (TECX) on October 13, 2026.